NAPLEX Quiz: Pharmacokinetic Parameters

What this quiz covers

This quiz focuses on Pharmacokinetic Parameters, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Levofloxacin 750 mg PO every 48 hours (correct answer)
2. Levofloxacin 250 mg PO every 24 hours
3. Levofloxacin 750 mg PO every 24 hours (no adjustment needed)
4. Levofloxacin 500 mg PO every 12 hours

Explanation: This question tests the application of renal dosage adjustment using the Cockcroft-Gault equation for calculating creatinine clearance. The key patient-specific factor is chronic kidney disease stage 3 with an elevated serum creatinine of 2.0 mg/dL, requiring dose adjustment for renally eliminated drugs like levofloxacin. The correct answer is levofloxacin 750 mg PO every 48 hours because the calculated CrCl = [(140-68) × 78] / (72 × 2.0) = 39 mL/min, which falls in the 20-49 mL/min range requiring the standard dose given every 48 hours instead of every 24 hours. Option B (250 mg every 24 hours) represents excessive dose reduction that may compromise efficacy. Option C (no adjustment) would risk accumulation and toxicity in renal impairment. Option D (500 mg every 12 hours) inappropriately increases the total daily dose. The clinical pearl is that fluoroquinolones require interval extension (not dose reduction) for CrCl 20-49 mL/min to maintain adequate peak concentrations while preventing accumulation: CrCl = [(140-age) × weight(kg)] / [72 × SCr(mg/dL)] × 0.85 if female.

Question 2

1. Decrease to vancomycin 750 mg IV every 12 hours
2. Increase to vancomycin 1,500 mg IV every 12 hours (correct answer)
3. Change to vancomycin 1,000 mg IV every 24 hours
4. No change; recheck trough in 48 hours

Explanation: The pharmacokinetic concept being tested is dose adjustment based on therapeutic drug monitoring using trough levels for vancomycin, assuming linear pharmacokinetics. The key patient-specific factor is stage 3 chronic kidney disease with SCr 1.8 mg/dL, reducing clearance and necessitating adjustments to achieve target troughs for MRSA bacteremia. Choice B is the best because increasing the dose to 1,500 mg every 12 hours proportionally raises the trough toward 15-20 mg/L, as current trough of 8 mg/L with 1,000 mg suggests linear scaling to approximately 12 mg/L, with further monitoring. Choice A decreases exposure, risking treatment failure; choice C reduces daily dose excessively; choice D maintains subtherapeutic levels. A clinical pearl is to adjust vancomycin doses using the ratio new dose = current dose × (target trough / current trough), assuming steady-state linear kinetics, and recheck levels after 3-5 doses to confirm AUC targets of 400-600 mg·h/L.

Question 3

1. Peak digoxin level 30 minutes after the dose
2. Trough digoxin level at steady state, drawn at least 6 hours after a dose (correct answer)
3. Urine digoxin concentration to estimate clearance
4. Free (unbound) digoxin level only, regardless of timing

Explanation: The pharmacokinetic concept being tested is therapeutic drug monitoring for narrow therapeutic index drugs like digoxin, focusing on steady-state trough levels. The key patient-specific factor is chronic kidney disease with SCr 1.6 mg/dL, which prolongs digoxin's half-life and requires careful monitoring to avoid toxicity. Choice B is the best because trough levels at steady state, drawn at least 6 hours post-dose, accurately reflect minimum concentrations and guide dosing adjustments for efficacy and safety in heart failure. Choice A is incorrect as peak levels do not correlate well with therapeutic effects; choice C is suboptimal because urine concentrations are not standard for digoxin monitoring; choice D ignores timing, which is critical for interpreting levels. A transferable pearl is to aim for digoxin troughs of 0.5-0.9 ng/mL in heart failure, using the formula for half-life t_{1/2} = 0.693 × V_d / Cl to estimate time to steady state, typically 5-7 days in normal renal function but longer in impairment.

Question 4

1. Enzyme induction by amiodarone causing increased warfarin clearance
2. Enzyme inhibition by amiodarone causing decreased warfarin clearance (correct answer)
3. Increased renal clearance of warfarin due to levothyroxine
4. Decreased absorption of warfarin due to levothyroxine

Explanation: This question tests understanding of drug interactions affecting warfarin metabolism through CYP450 inhibition. The key patient-specific factor is the recent addition of amiodarone to stable warfarin therapy, resulting in a supratherapeutic INR of 4.2. The correct answer is enzyme inhibition by amiodarone causing decreased warfarin clearance because amiodarone is a potent inhibitor of multiple CYP enzymes (CYP2C9, CYP3A4, CYP1A2) responsible for warfarin metabolism, leading to decreased clearance and increased anticoagulation. Option A incorrectly suggests enzyme induction, which would decrease INR. Options C and D incorrectly attribute the interaction to levothyroxine affecting renal clearance or absorption, but warfarin undergoes minimal renal excretion and the interaction mechanism is hepatic. The clinical pearl is that amiodarone typically requires a 30-50% warfarin dose reduction due to potent CYP inhibition, with effects persisting weeks after discontinuation due to amiodarone's long half-life.

Question 5

1. 0.7 hours
2. 1.0 hours
3. 2.3 hours (correct answer)
4. 5.0 hours

Explanation: This question tests the calculation of half-life from the elimination rate constant using first-order kinetics principles. The key pharmacokinetic parameter provided is the elimination rate constant (k = 0.30 hr⁻¹), which directly determines the drug's half-life independent of patient-specific factors. The correct answer is 2.3 hours because half-life = 0.693 / k = 0.693 / 0.30 hr⁻¹ = 2.31 hours, which rounds to 2.3 hours. Option A (0.7 hours) incorrectly divides k by 0.693. Option B (1.0 hour) doesn't follow the correct formula. Option D (5.0 hours) would correspond to a much smaller k value. The clinical pearl is that half-life is inversely related to the elimination rate constant and determines dosing frequency: t½ = 0.693 / k, where steady-state is reached after 5 half-lives.

Question 6

1. Cobicistat inhibition of CYP3A decreasing tacrolimus clearance (correct answer)
2. Tenofovir alafenamide induction of CYP3A increasing tacrolimus clearance
3. Emtricitabine increasing tacrolimus renal clearance
4. Normal liver enzymes eliminating the need to consider CYP interactions

Explanation: The pharmacokinetic concept being tested is drug-drug interactions via CYP3A inhibition affecting tacrolimus clearance post-transplant. The key patient-specific factor is cobicistat, a strong CYP3A inhibitor in the antiretroviral regimen, reducing tacrolimus metabolism. Choice A is the best because inhibition decreases clearance, increasing tacrolimus levels and requiring dose reductions to prevent toxicity. Choice B is incorrect as tenofovir does not induce CYP3A; choice C is wrong because emtricitabine does not affect renal clearance; choice D is suboptimal as normal enzymes do not negate interactions. A pearl is to reduce tacrolimus dose by 50-90% with strong inhibitors, monitoring troughs with target 5-15 ng/mL, using Cl = dose / (AUC) to guide adjustments.

Question 7

1. Smoking cessation decreasing theophylline clearance and increasing levels (correct answer)
2. Albuterol inducing CYP1A2 and increasing theophylline clearance
3. Normal SCr indicating increased theophylline renal clearance
4. Extended-release formulation increasing hepatic clearance

Explanation: The pharmacokinetic concept being tested is changes in hepatic clearance due to lifestyle factors like smoking cessation for CYP1A2 substrates such as theophylline. The key patient-specific factor is recent smoking cessation, which reduces CYP1A2 induction and decreases theophylline clearance, leading to elevated levels. Choice A is the best because it explains the increased exposure causing symptoms like nausea, requiring dose reduction. Choice B is incorrect as albuterol does not induce CYP1A2; choice C is wrong because normal SCr does not indicate increased renal clearance; choice D is suboptimal as formulation does not affect clearance. A pearl is to decrease theophylline dose by 25-50% upon smoking cessation, using clearance Cl = dose / Css, and monitor levels with target 8-15 mcg/mL, calculating half-life t_{1/2} = 0.693 × V_d / Cl.

Question 8

1. Half-life (correct answer)
2. Clearance
3. Elimination rate constant ($k$)
4. Bioavailability

Explanation: The pharmacokinetic concept being tested is the relationship between clearance, volume of distribution, and half-life for drugs like vancomycin. The key patient-specific factor is chronic kidney disease with SCr 1.5 mg/dL, directly reducing clearance and prolonging half-life. Choice A is the best because decreased clearance increases half-life ($t_{1/2}$ = 0.693 × V_d / Cl), assuming V_d unchanged, affecting dosing intervals. Choice B is incorrect as clearance decreases; choice C decreases with lower Cl; choice D is unaffected by renal changes. A pearl is to extend vancomycin intervals in renal impairment using t_{1/2} = 0.693 × V_d / Cl, estimating Cl from CrCl, and target troughs to guide therapy.

Question 9

1. TMP-SMX DS 1 tablet PO twice daily (no adjustment needed)
2. TMP-SMX DS 1 tablet PO daily (correct answer)
3. TMP-SMX DS 2 tablets PO twice daily
4. TMP-SMX single strength 1 tablet PO twice daily with no renal adjustment

Explanation: The pharmacokinetic concept being tested is renal dose adjustment for antibiotics like TMP-SMX in elderly patients with reduced kidney function. The key patient-specific factor is chronic kidney disease with SCr 1.7 mg/dL, estimating CrCl ≈20 mL/min and prolonging half-life. Choice B is the best because reducing to DS 1 tablet daily halves the dose to prevent accumulation and hyperkalemia. Choice A ignores impairment, risking toxicity; choice C increases dose inappropriately; choice D uses lower strength without adjustment, still excessive. A pearl is to use CrCl = [(140 - age) × weight] / [72 × SCr] × 0.85 for females, and for CrCl 15-30 mL/min, dose TMP-SMX at 50% of normal, monitoring for adverse effects like rash or hematologic changes.

Question 10

1. International normalized ratio (INR)
2. Activated partial thromboplastin time (aPTT) or anti-factor Xa level (correct answer)
3. Serum creatinine trend only
4. Aspartate aminotransferase (AST) weekly

Explanation: The pharmacokinetic concept being tested is laboratory monitoring of pharmacokinetic parameters for anticoagulants with narrow therapeutic indices like heparin. The key patient-specific factor is the need for real-time dose adjustments based on coagulation response, given heparin's variable clearance. Choice B is the best because aPTT or anti-Xa levels reflect heparin's effect on clotting and guide infusions to therapeutic ranges. Choice A is for vitamin K antagonists; choice C ignores direct monitoring; choice D is irrelevant for heparin. A pearl is to titrate heparin using aPTT (1.5-2.5 × baseline) or anti-Xa (0.3-0.7 units/mL), with bolus = 80 units/kg and infusion = 18 units/kg/h, adjusting based on levels every 6 hours initially.

Question 11

1. Acetaminophen 45 mg per dose every 6 hours as needed
2. Acetaminophen 60 mg per dose every 6 hours as needed
3. Acetaminophen 90 mg per dose every 6 hours as needed (correct answer)
4. Acetaminophen 120 mg per dose every 12 hours as needed

Explanation: The pharmacokinetic concept being tested is weight-based dosing to determine the appropriate maintenance dose for achieving therapeutic concentrations of acetaminophen in pediatric patients. The key patient-specific factor affecting pharmacokinetics is the infant's body weight of 6 kg, as acetaminophen is dosed per kilogram to account for variations in volume of distribution and clearance in infants. Choice C, acetaminophen 90 mg per dose every 6 hours as needed, is the best choice because it accurately calculates to 15 mg/kg × 6 kg = 90 mg, aligning with the recommended regimen for effective fever control without exceeding safe limits. Choices A (45 mg) and B (60 mg) represent underdosing, which could result in inadequate plasma concentrations and suboptimal therapeutic effect; choice D (120 mg every 12 hours) provides an excessive dose with prolonged interval, potentially leading to peaks above safe levels and troughs too low for sustained efficacy. A transferable clinical pearl is to always tailor doses in pediatrics using weight-based calculations to optimize pharmacokinetics and minimize toxicity risks. The decision framework involves the formula: dose (mg) = recommended dose (mg/kg) × patient weight (kg), followed by confirming the dosing interval based on the drug's elimination half-life, typically 2-4 hours for acetaminophen in infants, supporting every 6 hours administration.

Question 12

1. 155 mg IV once
2. 310 mg IV once (correct answer)
3. 620 mg IV once
4. 1,240 mg IV once

Explanation: The pharmacokinetic concept being tested is loading dose calculation for theophylline equivalents using volume of distribution in acute asthma. The key patient-specific factor is normal liver and renal function, supporting standard V_d use without adjustments. Choice B is the best because LD = 10 mg/L × 0.5 L/kg × 62 kg = 310 mg achieves the target theophylline concentration promptly. Choice A underdoses; choice C approximates but exceeds; choice D overdoses significantly. A pearl is to calculate aminophylline LD = C_{target} × V_d × weight / theophylline fraction (∼0.8), but use directly here, followed by infusion rate = Cl × Css, monitoring levels to avoid tachycardia.

Question 13

1. Approximately 1 hour
2. Approximately 3 hours (correct answer)
3. Approximately 6 hours
4. Approximately 12 hours

Explanation: The pharmacokinetic concept being tested is half-life estimation from concentration decline assuming first-order elimination for amikacin. The key patient-specific factor is chronic kidney disease with SCr 1.9 mg/dL, impacting clearance and extending half-life. Choice B is the best because k = ln(18/9)/3 = 0.231/h yields t_{1/2} = 0.693/0.231 ≈ 3 hours precisely. Choice A underestimates; choice C overestimates; choice D greatly overestimates. A pearl is to use k = ln(C1/C2)/Δt and t_{1/2} = 0.693/k for interval adjustments, ensuring levels are post-peak, and dose amikacin every 3-4 half-lives in renal impairment for troughs <5 mg/L.

Question 14

1. Fluoxetine inhibition significantly decreasing linezolid clearance via CYP450
2. Renal function has no impact on any drug's clearance
3. Linezolid clearance is not meaningfully affected by fluoxetine; no major PK interaction expected (correct answer)
4. Fluoxetine induction increasing linezolid clearance and reducing efficacy

Explanation: The pharmacokinetic concept being tested is the absence of significant pharmacokinetic interactions for linezolid, which has mixed renal and non-renal clearance. The key patient-specific factor is concomitant fluoxetine, but it does not alter linezolid's CYP-mediated metabolism meaningfully. Choice C is the best because no major PK interaction occurs, though PD serotonin risks exist separately. Choice A overstates inhibition; choice B ignores renal role; choice D misrepresents induction. A pearl is to assess linezolid clearance (Cl ≈ 7 L/h, unaffected by mild interactions), using dose / AUC for estimates, and monitor for myelosuppression rather than adjusting for fluoxetine PK effects.

Question 15

1. Elevated serum creatinine indicating reduced renal clearance (correct answer)
2. Concomitant omeprazole causing CYP2C19 inhibition
3. Sertraline increasing hepatic blood flow and clearance
4. Obesity primarily increasing enoxaparin hepatic metabolism

Explanation: The pharmacokinetic concept being tested is the impact of renal function on the clearance of anticoagulants like enoxaparin, which is primarily eliminated by the kidneys. The key patient-specific factor is impaired renal function, indicated by an elevated serum creatinine of 2.3 mg/dL and reduced creatinine clearance. Choice A is the best because elevated serum creatinine directly signals decreased renal clearance, necessitating dose adjustment to avoid bleeding risks. Choice B is incorrect as omeprazole does not significantly inhibit CYP2C19 for enoxaparin; choice C is wrong because sertraline does not increase hepatic blood flow; choice D is suboptimal as obesity affects volume of distribution more than hepatic metabolism for enoxaparin. A clinical pearl is to estimate creatinine clearance using Cockcroft-Gault with actual body weight for enoxaparin dosing, CrCl = [(140 - age) × weight (kg)] / [72 × SCr (mg/dL)] × 0.85 for females, and reduce dose by 50% if CrCl <30 mL/min to minimize accumulation.

Question 16

1. Enzyme induction by trimethoprim-sulfamethoxazole causing increased phenytoin clearance
2. Enzyme inhibition by trimethoprim-sulfamethoxazole causing decreased phenytoin clearance (correct answer)
3. Increased renal elimination of phenytoin due to omeprazole
4. Increased volume of distribution of phenytoin due to normal albumin

Explanation: This question tests understanding of drug-drug interactions affecting hepatic metabolism and clearance. The key patient-specific factor is the recent addition of trimethoprim-sulfamethoxazole to a stable phenytoin regimen, resulting in signs of phenytoin toxicity (nystagmus and ataxia). The correct answer is enzyme inhibition by trimethoprim-sulfamethoxazole causing decreased phenytoin clearance because trimethoprim is a known CYP2C9 inhibitor, and phenytoin is primarily metabolized by CYP2C9, leading to decreased clearance and accumulation. Option A incorrectly suggests enzyme induction, which would decrease levels. Option C incorrectly attributes the interaction to omeprazole affecting renal elimination, but phenytoin undergoes minimal renal excretion. Option D incorrectly focuses on volume of distribution, which doesn't explain the toxicity symptoms. The clinical pearl is that CYP450 inhibitors decrease drug clearance, increasing concentrations and risk of toxicity: common phenytoin metabolism inhibitors include trimethoprim, fluconazole, and amiodarone.

Question 17

1. Increased lithium clearance due to NSAID-associated increase in renal blood flow
2. Decreased lithium clearance due to NSAID-associated reduction in renal prostaglandins (correct answer)
3. Decreased lithium clearance due to CYP3A4 inhibition by ibuprofen
4. Increased lithium clearance due to decreased tubular reabsorption from ibuprofen

Explanation: This question tests understanding of drug interactions affecting renal clearance of lithium. The key patient-specific factor is the recent addition of ibuprofen (an NSAID) to stable lithium therapy, resulting in an elevated lithium level of 1.6 mEq/L. The correct answer is decreased lithium clearance due to NSAID-associated reduction in renal prostaglandins because NSAIDs inhibit prostaglandin synthesis, which reduces renal blood flow and glomerular filtration rate, thereby decreasing lithium clearance and causing accumulation. Option A incorrectly suggests increased clearance and renal blood flow. Option C incorrectly invokes CYP3A4 inhibition, but lithium is not metabolized by CYP enzymes. Option D incorrectly suggests increased clearance through decreased reabsorption. The clinical pearl is that NSAIDs (except aspirin ≤ 325 mg/day) decrease lithium clearance by 20-25% through prostaglandin inhibition, requiring dose reduction or NSAID discontinuation to prevent toxicity.

Question 18

1. 1.7 mg/kg IV every 8 hours (no adjustment needed)
2. 1.7 mg/kg IV every 24 hours (correct answer)
3. 3 mg/kg IV every 8 hours
4. 0.85 mg/kg IV every 8 hours

Explanation: This question tests renal dose adjustment for aminoglycosides using extended-interval dosing principles. The key patient-specific factor is severe renal impairment with serum creatinine 2.6 mg/dL in an elderly patient, requiring significant adjustment of tobramycin dosing. The correct answer is 1.7 mg/kg IV every 24 hours because the calculated CrCl = [(140-80) × 68] / (72 × 2.6) = 21.8 mL/min, which is less than 30 mL/min, requiring interval extension to every 24 hours while maintaining the same dose to achieve adequate peak concentrations. Option A (no adjustment) risks severe accumulation and nephrotoxicity. Option C inappropriately increases the dose. Option D reduces the dose, which may compromise efficacy by not achieving adequate peaks. The clinical pearl is that aminoglycosides require interval extension (not dose reduction) in renal impairment to maintain bactericidal peak concentrations while allowing clearance between doses: extend interval when CrCl < 60 mL/min.

Question 19

1. Enoxaparin 1 mg/kg subcutaneously every 24 hours (correct answer)
2. Enoxaparin 40 mg subcutaneously every 24 hours
3. Enoxaparin 1 mg/kg subcutaneously every 8 hours
4. Enoxaparin 1 mg/kg subcutaneously every 12 hours (no adjustment needed)

Explanation: This question tests renal dose adjustment for low molecular weight heparins in chronic kidney disease. The key patient-specific factor is severe renal impairment with a serum creatinine of 2.2 mg/dL in an elderly female, requiring adjustment of enoxaparin dosing. The correct answer is enoxaparin 1 mg/kg subcutaneously every 24 hours because the calculated CrCl = [(140-74) × 60 × 0.85] / (72 × 2.2) = 21.3 mL/min, which is less than 30 mL/min, requiring interval extension from every 12 hours to every 24 hours for treatment dosing. Option B (40 mg daily) is a prophylactic dose, not treatment. Option C (every 8 hours) inappropriately increases frequency. Option D (no adjustment) risks accumulation and bleeding in severe renal impairment. The clinical pearl is that enoxaparin requires interval extension (not dose reduction) when CrCl < 30 mL/min for treatment dosing: CrCl = [(140-age) × weight × 0.85] / (72 × SCr) for females.

Question 20

1. Digoxin 0.25 mg PO daily
2. Digoxin 0.125 mg PO every other day
3. Digoxin 0.0625 mg PO daily (correct answer)
4. Digoxin 0.1875 mg PO daily

Explanation: This question tests proportional dose adjustment using steady-state concentration data and linear pharmacokinetics principles. The key patient-specific factor is a supratherapeutic digoxin level of 1.6 ng/mL in a patient with chronic kidney disease, requiring dose reduction to achieve the target range of 0.5-0.9 ng/mL. The correct answer is 0.0625 mg PO daily because using proportional dosing: New Dose = Current Dose × (Target Concentration / Current Concentration) = 0.125 mg × (0.7 ng/mL / 1.6 ng/mL) = 0.0547 mg, which rounds to the available strength of 0.0625 mg. Option B (0.125 mg every other day) equals 0.0625 mg daily but may cause fluctuating levels. Option D (0.1875 mg) would maintain levels above target. The clinical pearl is that for drugs with linear kinetics, dose adjustments are directly proportional to the ratio of desired to current steady-state concentrations: New Dose = Old Dose × (Cp target / Cp current).